A new paper authored by two Food and Drug Administration (FDA) employees argues that the recent spate of drug shortages was caused by numerous factors, all of which can be tied to low prices for the drugs. The lack of adherence to quality standards and low rates of redundancies are directly tied to manufacturer resources. The paper proposes that quality be included in information about the drugs. Much of the recent discussion around drug shortages is related to reimbursement, which is the amount Medicare pays the provider for the drug, rather than price.
The Alliance continues to advocate for access to safe and effective drugs.
Read the paper here
Learn more about drug shortages here